东诚药业(002675.SZ)：肝素钠原料药通过美国FDA检查

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) successfully passed the FDA's cGMP inspection for heparin sodium raw materials, enhancing its competitiveness in the international market and supporting its expansion into the global market [1] Group 1 - The company underwent an FDA cGMP inspection from December 8 to December 11, 2025 [1] - The company received the Establishment Inspection Report (EIR) from the FDA, confirming compliance with cGMP requirements [1] - The successful inspection indicates the company's quality system continues to meet FDA standards, providing a solid foundation for expanding its heparin sodium raw materials in the U.S. market [1]